Healthcare Global Enterprises Ltd

Health.Global Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Healthcare Global Enterprises Ltd

₹ 375 -0.78%
02 Jul - close price
hcgoncology.com BSE: 539787 NSE: HCG
About

Healthcare Global Enterprises Ltd is engaged in setting up and managing hospitals and medical diagnostic services including scientific testing and consultancy services in the pharmaceutical and medical sector.[1]

Key Points

Service Offering
The Company is a provider of specialty healthcare focused on cancer and fertility. Under the “HCG” brand, it operates the largest cancer care network in India in terms of the total number of private cancer treatment centers licensed by the AERB. It also provides fertility treatment under our “Milann” brand. [1]

Website BSE NSE
  • Market Cap ₹ 5,222 Cr.
  • Current Price ₹ 375
  • High / Low ₹ 401 / 306
  • Stock P/E 133
  • Book Value ₹ 59.3
  • Dividend Yield 0.00 %
  • ROCE 8.83 %
  • ROE 4.67 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has delivered good profit growth of 29.2% CAGR over last 5 years

Cons

  • Stock is trading at 6.32 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.
  • Company has a low return on equity of 2.08% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Healthcare Industry: Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
298 323 352 358 365 408 420 425 442 461 487 470 495
259 272 292 296 301 336 345 349 365 386 402 391 403
Operating Profit 39 51 60 62 63 72 75 76 76 74 85 79 92
OPM % 13% 16% 17% 17% 17% 18% 18% 18% 17% 16% 17% 17% 19%
-79 4 143 -43 3 3 2 4 5 3 3 6 9
Interest 26 26 23 24 24 25 26 27 26 26 27 29 27
Depreciation 38 38 38 41 41 40 41 41 42 41 43 44 46
Profit before tax -104 -9 142 -46 1 10 10 11 13 11 18 11 28
Tax % -9% -40% 30% -8% -145% 76% 47% 63% 57% 65% 40% 69% 17%
-114 -13 99 -50 2 2 5 4 6 4 11 3 23
EPS in Rs -8.15 -0.76 8.22 -3.29 0.43 0.44 0.53 0.54 0.60 0.55 0.97 0.41 1.53
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
338 451 519 584 700 829 976 1,092 1,009 1,395 1,691 1,912
292 413 443 499 595 713 864 936 887 1,161 1,394 1,583
Operating Profit 47 38 76 85 105 116 112 157 122 234 297 330
OPM % 14% 9% 15% 15% 15% 14% 11% 14% 12% 17% 18% 17%
2 3 0 -2 10 25 10 10 -72 110 15 21
Interest 29 32 34 38 23 42 70 138 119 98 104 109
Depreciation 30 36 39 44 57 71 85 148 159 158 163 174
Profit before tax -10 -27 3 0 35 27 -33 -119 -229 88 45 68
Tax % -7% -20% -56% -730% 34% 38% 7% -5% 3% 56% 61% 39%
-11 -32 5 2 23 17 -31 -125 -221 39 18 41
EPS in Rs -1.54 -5.21 0.12 -0.17 2.59 2.36 -2.82 -12.03 -15.43 3.87 2.11 3.46
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 16%
5 Years: 14%
3 Years: 24%
TTM: 13%
Compounded Profit Growth
10 Years: 13%
5 Years: 29%
3 Years: 33%
TTM: 117%
Stock Price CAGR
10 Years: %
5 Years: 21%
3 Years: 19%
1 Year: 17%
Return on Equity
10 Years: -3%
5 Years: -5%
3 Years: 2%
Last Year: 5%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 67 68 70 85 86 87 88 89 125 139 139 139
Reserves 217 196 210 341 347 428 389 293 528 731 721 686
308 292 349 324 420 464 658 1,347 977 915 901 1,274
116 133 147 294 372 461 515 518 401 433 549 607
Total Liabilities 708 688 776 1,043 1,225 1,440 1,650 2,246 2,031 2,218 2,311 2,708
508 512 528 583 685 828 970 1,646 1,382 1,547 1,553 1,758
CWIP 0 11 42 121 148 174 153 46 30 22 18 83
Investments 61 2 0 64 11 53 49 34 26 9 10 10
139 164 205 275 381 385 478 520 593 641 730 856
Total Assets 708 688 776 1,043 1,225 1,440 1,650 2,246 2,031 2,218 2,311 2,708

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
31 51 60 73 91 98 98 130 121 220 252 285
-178 -12 -79 -204 -210 -283 -238 -101 -171 125 -133 -226
140 -27 22 216 89 161 84 -58 112 -155 -140 -64
Net Cash Flow -7 13 2 85 -29 -24 -56 -30 62 190 -22 -5

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 65 43 45 43 54 57 59 62 67 57 65 56
Inventory Days 35 33 36 32 40 46 45 35 32 31 33 33
Days Payable 186 193 208 264 272 274 303 234 221 199 214 216
Cash Conversion Cycle -86 -117 -127 -188 -178 -171 -200 -136 -121 -112 -116 -127
Working Capital Days -4 -20 -44 -72 -90 -73 -92 -70 33 -21 -22 -26
ROCE % 4% 1% 7% 6% 7% 6% 3% 1% -1% 5% 8%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
68.41% 68.40% 71.44% 71.43% 71.42% 71.39% 71.39% 71.37% 71.35% 71.30% 71.29% 71.28%
6.42% 7.24% 7.03% 6.99% 7.22% 7.27% 7.18% 6.37% 6.47% 6.29% 6.37% 6.74%
9.69% 8.16% 6.59% 5.86% 4.55% 4.02% 4.41% 5.53% 6.58% 7.94% 8.46% 8.52%
15.48% 16.19% 14.94% 15.73% 16.81% 17.32% 17.04% 16.71% 15.59% 14.49% 13.89% 13.45%
No. of Shareholders 15,06520,57322,36223,66323,01824,67228,70728,85825,93127,32727,28927,195

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls